Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Drugging MYCN oncogenic signalling through the MYCN-PA2G4 binding interface.

Koach J, Holien JK, Massudi H, Carter DR, Ciampa OC, Herath M, Lim T, Seneviratne JA, Milazzo G, Murray JE, McCarroll JA, Liu B, Mayoh C, Keenan B, Stevenson BW, Gorman MA, Bell JL, Doughty L, Hüttelmaier S, Oberthuer A, Fischer M, Gifford AJ, Liu T, Zhang X, Zhu S, Gustafson WC, Haber M, Norris MD, Fletcher JI, Perini G, Parker MW, Cheung BB, Marshall GM.

Cancer Res. 2019 Sep 9. pii: canres.1112.2019. doi: 10.1158/0008-5472.CAN-19-1112. [Epub ahead of print]

PMID:
31501192
2.

Increase in DNA Damage by MYCN Knockdown Through Regulating Nucleosome Organization and Chromatin State in Neuroblastoma.

Hu X, Zheng W, Zhu Q, Gu L, Du Y, Han Z, Zhang X, Carter DR, Cheung BB, Qiu A, Jiang C.

Front Genet. 2019 Jul 24;10:684. doi: 10.3389/fgene.2019.00684. eCollection 2019.

3.

JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.

Wong M, Sun Y, Xi Z, Milazzo G, Poulos RC, Bartenhagen C, Bell JL, Mayoh C, Ho N, Tee AE, Chen X, Li Y, Ciaccio R, Liu PY, Jiang CC, Lan Q, Jayatilleke N, Cheung BB, Haber M, Norris MD, Zhang XD, Marshall GM, Wang JY, Hüttelmaier S, Fischer M, Wong JWH, Xu H, Perini G, Dong Q, George RE, Liu T.

Nat Commun. 2019 Jul 25;10(1):3319. doi: 10.1038/s41467-019-11132-w.

4.

Heterozygous loss of keratinocyte TRIM16 expression increases melanocytic cell lesions and lymph node metastasis.

Sutton SK, Cheung BB, Massudi H, Tan O, Koach J, Mayoh C, Carter DR, Marshall GM.

J Cancer Res Clin Oncol. 2019 Sep;145(9):2241-2250. doi: 10.1007/s00432-019-02981-5. Epub 2019 Jul 24.

5.

Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma.

Gamble LD, Purgato S, Murray J, Xiao L, Yu DMT, Hanssen KM, Giorgi FM, Carter DR, Gifford AJ, Valli E, Milazzo G, Kamili A, Mayoh C, Liu B, Eden G, Sarraf S, Allan S, Di Giacomo S, Flemming CL, Russell AJ, Cheung BB, Oberthuer A, London WB, Fischer M, Trahair TN, Fletcher JI, Marshall GM, Ziegler DS, Hogarty MD, Burns MR, Perini G, Norris MD, Haber M.

Sci Transl Med. 2019 Jan 30;11(477). pii: eaau1099. doi: 10.1126/scitranslmed.aau1099.

PMID:
30700572
6.

Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.

Ooi CY, Carter DR, Liu B, Mayoh C, Beckers A, Lalwani A, Nagy Z, De Brouwer S, Decaesteker B, Hung TT, Norris MD, Haber M, Liu T, De Preter K, Speleman F, Cheung BB, Marshall GM.

Cancer Res. 2018 Jun 15;78(12):3122-3134. doi: 10.1158/0008-5472.CAN-17-3034. Epub 2018 Apr 2.

7.

The regulatory role of long noncoding RNAs in cancer.

Tang Y, Cheung BB, Atmadibrata B, Marshall GM, Dinger ME, Liu PY, Liu T.

Cancer Lett. 2017 Apr 10;391:12-19. doi: 10.1016/j.canlet.2017.01.010. Epub 2017 Jan 19. Review.

PMID:
28111137
8.

The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.

Liu PY, Sokolowski N, Guo ST, Siddiqi F, Atmadibrata B, Telfer TJ, Sun Y, Zhang L, Yu D, Mccarroll J, Liu B, Yang RH, Guo XY, Tee AE, Itoh K, Wang J, Kavallaris M, Haber M, Norris MD, Cheung BB, Byrne JA, Ziegler DS, Marshall GM, Dinger ME, Codd R, Zhang XD, Liu T.

Oncotarget. 2016 Nov 29;7(48):79217-79232. doi: 10.18632/oncotarget.12640.

9.

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.

Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, de Preter K, Decock A, Patil N, Abba M, Kopp-Schneider A, Astrahantseff K, Wünschel J, Pfeil S, Ercu M, Künkele A, Hu J, Thole T, Schweizer L, Mechtersheimer G, Carter D, Cheung BB, Popanda O, von Deimling A, Koster J, Versteeg R, Schwab M, Marshall GM, Speleman F, Erb U, Zoeller M, Allgayer H, Simon T, Fischer M, Kulozik AE, Eggert A, Witt O, Schulte JH, Deubzer HE.

Oncotarget. 2016 Oct 11;7(41):66344-66359. doi: 10.18632/oncotarget.11662.

10.

MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.

Xue C, Yu DM, Gherardi S, Koach J, Milazzo G, Gamble L, Liu B, Valli E, Russell AJ, London WB, Liu T, Cheung BB, Marshall GM, Perini G, Haber M, Norris MD.

Oncotarget. 2016 Aug 23;7(34):54937-54951. doi: 10.18632/oncotarget.10709.

11.

A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner.

Sutton SK, Carter DR, Kim P, Tan O, Arndt GM, Zhang XD, Baell J, Noll BD, Wang S, Kumar N, McArthur GA, Cheung BB, Marshall GM.

Oncotarget. 2016 Aug 9;7(32):52166-52178. doi: 10.18632/oncotarget.10700.

12.

Synthesis, Characterization and Anti-Cancer Activity of Hydrazide Derivatives Incorporating a Quinoline Moiety.

Bingul M, Tan O, Gardner CR, Sutton SK, Arndt GM, Marshall GM, Cheung BB, Kumar N, Black DS.

Molecules. 2016 Jul 14;21(7). pii: E916. doi: 10.3390/molecules21070916.

13.

Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.

Carter DR, Sutton SK, Pajic M, Murray J, Sekyere EO, Fletcher J, Beckers A, De Preter K, Speleman F, George RE, Haber M, Norris MD, Cheung BB, Marshall GM.

Mol Oncol. 2016 Jun;10(6):866-78. doi: 10.1016/j.molonc.2016.02.004. Epub 2016 Mar 2.

14.

High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients.

Kim PY, Tan O, Liu B, Trahair T, Liu T, Haber M, Norris MD, Marshall GM, Cheung BB.

Cancer Lett. 2016 May 1;374(2):315-23. doi: 10.1016/j.canlet.2016.02.021. Epub 2016 Feb 20.

PMID:
26902425
15.

The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression.

Tee AE, Liu B, Song R, Li J, Pasquier E, Cheung BB, Jiang C, Marshall GM, Haber M, Norris MD, Fletcher JI, Dinger ME, Liu T.

Oncotarget. 2016 Feb 23;7(8):8663-75. doi: 10.18632/oncotarget.6675.

16.

Combination therapies improve the anticancer activities of retinoids in neuroblastoma.

Cheung BB.

World J Clin Oncol. 2015 Dec 10;6(6):212-5. doi: 10.5306/wjco.v6.i6.212.

17.

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, Sutton S, Kalla H, Syed S, Gifford AJ, Issaeva N, Biktasova A, Atmadibrata B, Sun Y, Sokolowski N, Ling D, Kim PY, Webber H, Clark A, Ruhle M, Liu B, Oberthuer A, Fischer M, Byrne J, Saletta F, Thwe le M, Purmal A, Haderski G, Burkhart C, Speleman F, De Preter K, Beckers A, Ziegler DS, Liu T, Gurova KV, Gudkov AV, Norris MD, Haber M, Marshall GM.

Sci Transl Med. 2015 Nov 4;7(312):312ra176. doi: 10.1126/scitranslmed.aab1803.

18.

MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.

Beckers A, Van Peer G, Carter DR, Gartlgruber M, Herrmann C, Agarwal S, Helsmoortel HH, Althoff K, Molenaar JJ, Cheung BB, Schulte JH, Benoit Y, Shohet JM, Westermann F, Marshall GM, Vandesompele J, De Preter K, Speleman F.

Cancer Lett. 2015 Sep 28;366(1):123-32. doi: 10.1016/j.canlet.2015.06.015. Epub 2015 Jun 26.

19.

Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Cheung BB, Tan O, Koach J, Liu B, Shum MS, Carter DR, Sutton S, Po'uha ST, Chesler L, Haber M, Norris MD, Kavallaris M, Liu T, O'Neill GM, Marshall GM.

Mol Oncol. 2015 Aug;9(7):1484-500. doi: 10.1016/j.molonc.2015.04.005. Epub 2015 Apr 29.

20.

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.

Lambertz I, Kumps C, Claeys S, Lindner S, Beckers A, Janssens E, Carter DR, Cazes A, Cheung BB, De Mariano M, De Bondt A, De Brouwer S, Delattre O, Gibbons J, Janoueix-Lerosey I, Laureys G, Liang C, Marchall GM, Porcu M, Takita J, Trujillo DC, Van Den Wyngaert I, Van Roy N, Van Goethem A, Van Maerken T, Zabrocki P, Cools J, Schulte JH, Vialard J, Speleman F, De Preter K.

Clin Cancer Res. 2015 Jul 15;21(14):3327-39. doi: 10.1158/1078-0432.CCR-14-2024. Epub 2015 Mar 24.

21.

TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells.

Sutton SK, Koach J, Tan O, Liu B, Carter DR, Wilmott JS, Yosufi B, Haydu LE, Mann GJ, Thompson JF, Long GV, Liu T, McArthur G, Zhang XD, Scolyer RA, Cheung BB, Marshall GM.

Oncotarget. 2014 Oct 30;5(20):10127-39.

22.

MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation.

Beckers A, Van Peer G, Carter DR, Mets E, Althoff K, Cheung BB, Schulte JH, Mestdagh P, Vandesompele J, Marshall GM, De Preter K, Speleman F.

Oncotarget. 2015 Mar 10;6(7):5204-16.

23.

Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.

Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M, Liu B, Bell JL, Zhang XD, Milazzo G, Cheung BB, Fox A, Swarbrick A, Hüttelmaier S, Kavallaris M, Perini G, Mattick JS, Dinger ME, Liu T.

J Natl Cancer Inst. 2014 Jun 6;106(7). pii: dju113. doi: 10.1093/jnci/dju113. Print 2014 Jul. Erratum in: J Natl Cancer Inst. 2015 Jan;107(1):doi/10.1093/jnci/dju359.

24.

The prenatal origins of cancer.

Marshall GM, Carter DR, Cheung BB, Liu T, Mateos MK, Meyerowitz JG, Weiss WA.

Nat Rev Cancer. 2014 Apr;14(4):277-89. doi: 10.1038/nrc3679. Epub 2014 Mar 6. Review.

25.

Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach.

Kim PY, Tan O, Diakiw SM, Carter D, Sekerye EO, Wasinger VC, Liu T, Kavallaris M, Norris MD, Haber M, Chesler L, Dolnikov A, Trahair TN, Cheung NK, Marshall GM, Cheung BB.

J Proteomics. 2014 Jan 16;96:1-12. doi: 10.1016/j.jprot.2013.10.032. Epub 2013 Nov 4.

26.

TRIM16 inhibits neuroblastoma cell proliferation through cell cycle regulation and dynamic nuclear localization.

Bell JL, Malyukova A, Kavallaris M, Marshall GM, Cheung BB.

Cell Cycle. 2013 Mar 15;12(6):889-98. doi: 10.4161/cc.23825. Epub 2013 Feb 19.

27.

TRIM16 overexpression induces apoptosis through activation of caspase-2 in cancer cells.

Kim PY, Rahmanto AS, Tan O, Norris MD, Haber M, Marshall GM, Cheung BB.

Apoptosis. 2013 May;18(5):639-51. doi: 10.1007/s10495-013-0813-y.

28.

The histone deacetylase SIRT2 stabilizes Myc oncoproteins.

Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, Ling D, Su SP, Nelson C, Chang DK, Koach J, Tee AE, Haber M, Norris MD, Toon C, Rooman I, Xue C, Cheung BB, Kumar S, Marshall GM, Biankin AV, Liu T.

Cell Death Differ. 2013 Mar;20(3):503-14. doi: 10.1038/cdd.2012.147. Epub 2012 Nov 23.

29.

Synthesis of retinoid enhancers based on 2-aminobenzothiazoles for anti-cancer therapy.

Gardner CR, Cheung BB, Koach J, Black DS, Marshall GM, Kumar N.

Bioorg Med Chem. 2012 Dec 1;20(23):6877-84. doi: 10.1016/j.bmc.2012.09.035. Epub 2012 Oct 3.

PMID:
23088909
30.

Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.

Calao M, Sekyere EO, Cui HJ, Cheung BB, Thomas WD, Keating J, Chen JB, Raif A, Jankowski K, Davies NP, Bekkum MV, Chen B, Tan O, Ellis T, Norris MD, Haber M, Kim ES, Shohet JM, Trahair TN, Liu T, Wainwright BJ, Ding HF, Marshall GM.

Oncogene. 2013 Aug 1;32(31):3616-26. doi: 10.1038/onc.2012.368. Epub 2012 Aug 20.

PMID:
22907436
31.

TRIM16 acts as an E3 ubiquitin ligase and can heterodimerize with other TRIM family members.

Bell JL, Malyukova A, Holien JK, Koach J, Parker MW, Kavallaris M, Marshall GM, Cheung BB.

PLoS One. 2012;7(5):e37470. doi: 10.1371/journal.pone.0037470. Epub 2012 May 21.

32.

The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro.

Cheung BB, Koach J, Tan O, Kim P, Bell JL, D'andreti C, Sutton S, Malyukova A, Sekyere E, Norris M, Haber M, Kavallaris M, Cunningham AM, Proby C, Leigh I, Wilmott JS, Cooper CL, Halliday GM, Scolyer RA, Marshall GM.

J Pathol. 2012 Feb;226(3):451-62. doi: 10.1002/path.2986. Epub 2011 Oct 18.

33.

Targeting ATP7A to increase the sensitivity of neuroblastoma cells to retinoid therapy.

Cheung BB, Marshall GM.

Curr Cancer Drug Targets. 2011 Sep;11(7):826-36. Review.

PMID:
21762080
34.

TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells.

Marshall GM, Bell JL, Koach J, Tan O, Kim P, Malyukova A, Thomas W, Sekyere EO, Liu T, Cunningham AM, Tobias V, Norris MD, Haber M, Kavallaris M, Cheung BB.

Oncogene. 2010 Nov 18;29(46):6172-83. doi: 10.1038/onc.2010.340. Epub 2010 Aug 23.

35.

The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation.

Raif A, Marshall GM, Bell JL, Koach J, Tan O, D'andreti C, Thomas W, Sekyere E, Norris M, Haber M, Kavallaris M, Cheung BB.

Cancer Lett. 2009 May 8;277(1):82-90. doi: 10.1016/j.canlet.2008.11.030. Epub 2009 Jan 14.

PMID:
19147277
36.

ATP7A is a novel target of retinoic acid receptor beta2 in neuroblastoma cells.

Bohlken A, Cheung BB, Bell JL, Koach J, Smith S, Sekyere E, Thomas W, Norris M, Haber M, Lovejoy DB, Richardson DR, Marshall GM.

Br J Cancer. 2009 Jan 13;100(1):96-105. doi: 10.1038/sj.bjc.6604833.

37.

The estrogen-responsive B box protein is a novel regulator of the retinoid signal.

Cheung BB, Bell J, Raif A, Bohlken A, Yan J, Roediger B, Poljak A, Smith S, Lee M, Thomas WD, Kavallaris M, Norris M, Haber M, Liu HL, Zajchowski D, Marshall GM.

J Biol Chem. 2006 Jun 30;281(26):18246-56. Epub 2006 Apr 24.

Supplemental Content

Loading ...
Support Center